Fig. 7From: Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvantsPercentages of patients with different VEGF-specific IgG subclasses in the weeks 5–16, 20–36 and 46–56. In each of these stages, and for the available patients, the study was made in the sample with the highest specific IgG antibody titer. “n” represents the number of evaluated patients. Terms “non-detectable”, “detectable” and “predominant” are detailed in MethodsBack to article page